Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial

Fig. 2

Least squares mean change from baseline versus placebo in trough FEV1 L (full analysis set). Baseline was defined separately for each treatment period as the average of the 60 and 30 minutes pre-dose measurements taken on day 1 of each treatment period. Error bars represent 95% confidence intervals. * p = 0.011, ** p = 0.009, QD once daily, FEV1 forced expiratory volume in 1 second, L liters, NS not significant

Back to article page